UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1268-7
Program Prior Authorization/Notification
Medication Sucraid (sacrosidase) oral solution
P&T Approval Date 12/2018, 12/2019, 1/2021, 1/2022, 1/2023, 1/2024, 1/2024
Effective Date 4/1/2025
1. Background:
Sucraid (sacrosidase) is an oral enzyme replacement therapy indicated for the treatment of sucrase
deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID). The effects of
Sucraid have not been evaluated in patients with secondary (acquired) sucrase deficiency.
2. Coverage Criteriona:
A. Initial Authorization
1. Sucraid will be approved based on the following criterion:
a. Diagnosis of congenital sucrase-isomaltase deficiency.
Authorization will be issued for 12 months.
B. Reauthorization
1. Sucraid will be approved based on the following criterion:
a. Documentation of positive clinical response to Sucraid therapy.
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class
4. References:
1. Sucraid [package insert]. Vero Beach, FL: QOL Medical, LLC; August 2024.
© 2025 UnitedHealthcare Services, Inc.
1
Program Prior Authorization/Notification – Sucraid
Change Control
12/2018 New program
12/2019 Annual review, no changes.
1/2021 Annual review. Updated references.
1/2022 Annual review with no changes to coverage criteria. Updated
reference.
1/2023 Annual review with no changes to coverage criteria. Added state
mandate footnote and updated reference.
1/2024 Annual review with no changes to coverage criteria. Updated
reference.
1/2025 Annual review with no changes to coverage criteria. Updated
background and reference.
© 2025 UnitedHealthcare Services, Inc.
2